The lobbying group for the U.S. pharmaceutical industry, the Pharmaceutical Research & Manufacturers of America, spent an estimated $59 million on paid search advertising over a recent seven-year period, investigators reported. The article summarized a published analysis that modeled the spending from 2019 through 2025.
The study team broke the estimated total into two primary streams. About $32 million was spent on ads tied to searches for insurance and health-plan topics, the authors noted. Another roughly $28 million directed users to web pages and domains that criticized pharmacy benefit managers — the entities drugmakers point to when assigning blame for rising medicine costs. The STAT report presented those dollar figures as central outcomes of the analysis.
The researchers identified a broad keyword strategy. They reported more than 283,500 distinct keywords were used to trigger paid search placements. That large keyword inventory, the analysis indicated, generated an estimated 17.1 million paid visits to PhRMA-linked landing pages and domains between 2019 and 2025.
Those visit and keyword totals suggest a high-volume campaign designed to capture users across many search intents. The STAT summary did not provide platform-level detail, however, and the article did not list specific keywords or the relative cost per keyword. The published analysis in Clinical Pharmacology & Therapeutics was cited as the source for the modeled figures.
The analysis reported temporal variation in spending. Data indicated spending surged around well-publicized legislative and regulatory actions, with a noticeable increase when Medicare began drug price negotiations in 2023. The study team observed that campaign intensity tracked major policy moments, implying deliberate timing to influence public discourse as negotiations and regulatory changes unfolded.
The STAT piece emphasized those temporal patterns as part of the narrative linking ad buys to policy debates. The article did not, however, present the underlying daily or weekly spending series, nor did it reproduce the timeline plots from the Clinical Pharmacology & Therapeutics paper. Readers who seek that granularity must consult the original analysis.
The core figures summarized by STAT come from a modeling exercise published in Clinical Pharmacology & Therapeutics. That paper, according to the STAT article, estimated the $59 million total, apportioned roughly into $32 million for insurance-related search terms and $28 million for content criticizing PBMs, and calculated the 17.1 million paid visits tied to more than 283,500 keywords.
STAT’s coverage presented those outputs but did not include detailed methodological specifics in the news summary. The article did not report exact modeling assumptions, the data sources used for keyword identification, platform-specific bidding behavior, or a breakdown of spending by year beyond the broad 2019–2025 window. Investigators reported the main outcomes within the peer-reviewed paper; the STAT story linked to that paper as its evidence base.
The piece also noted that spending surged at particular policy moments, such as the beginning of Medicare drug price negotiations in 2023. STAT framed that temporal association as part of the analysis’ findings without reproducing the supporting figures or statistical tests.
Limitations and outstanding questions documented in the source
The STAT summary makes clear that the numbers derive from modeled estimates drawn from the published analysis. The article did not describe in full the modeling approach, nor did it supply platform-level ad data or a list of specific keywords. Those omissions leave questions for readers interested in the methods: how the authors attributed paid visits to PhRMA specifically, which advertising platforms were included, and how search-intent categories were classified. The STAT article itself recommended consulting the Clinical Pharmacology & Therapeutics paper for the technical details.
The reporting was presented as a STAT+ exclusive; the news summary linked readers to the peer-reviewed analysis as the primary source of the estimated totals and patterns. The figures reported in the article — the $59 million total, the roughly $32 million and $28 million category splits, the 283,500 keyword count, and the 17.1 million paid visits — reflect the published analysis as summarized by STAT's coverage.
No further regulatory actions, legal responses, or industry rebuttals were detailed in the article’s summary. For readers seeking those follow-up items or deeper methodological transparency, the STAT piece points back to the journal publication as the source to examine next.